MicroRNA‑301a‑3p promotes triple‑negative breast cancer progression through downregulating MEOX2

Liu,Heng; Wang,Gangyue

doi:10.3892/etm.2021.10377

MicroRNA‑301a‑3p promotes triple‑negative breast cancer progression through downregulating MEOX2

Authors:
- Heng Liu
- Gangyue Wang
View Affiliations

Affiliations: Department of Breast Surgery, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing 100006, P.R. China
Published online on: July 1, 2021 https://doi.org/10.3892/etm.2021.10377
Article Number: 945
Copyright: © Liu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Breast cancer is one of the most frequently diagnosed malignancies among women. Triple‑negative breast cancer (TNBC) represents a significant challenge for breast oncologists, as the availability of effective therapies for this aggressive disease is limited. The molecular mechanisms underlying TNBC development are not fully understood. Previous studies have demonstrated that microRNAs (miRNAs/miRs) play important roles in the development of various types of cancer, including breast cancer; however, the role of miRNAs in TNBC remains undetermined. The results of the present study revealed that miR‑301a‑3p may function as an oncogenic miRNA in TNBC. Based on The Cancer Genome Atlas data, miR‑301a‑3p expression levels were found to be upregulated in breast cancer tissues. Reverse transcription‑quantitative PCR analysis demonstrated that the expression levels of miR‑301a‑3p were upregulated in TNBC tissues compared with non‑TNBC tissues, and in MDA‑MB‑231 cells compared with normal MCF‑10A breast cells. miR‑301a‑3p mimics and inhibitors were subsequently used to overexpress and knock down miR‑301a‑3p expression, respectively, in MDA‑MB‑231 cells. Biological functional experiments demonstrated that miR‑301a‑3p overexpression increased the viability, and the migratory and invasive abilities of MDA‑MB‑231 cells. By contrast, miR‑301a‑3p knockdown exerted the opposite effects on MDA‑MB‑231 cells. Cell apoptosis was negatively regulated by miR‑301a‑3p. Moreover, overexpression of miR‑301a‑3p was found to downregulate the expression levels of mesenchyme homeobox 2 (MEOX2). The expression levels of miR‑301a‑3p were negatively correlated with the expression levels of MEOX2 in clinical tissue specimens from patients with TNBC. Subsequently, the knockdown of MEOX2 expression promoted the viability of MDA‑MB‑231 cells. In conclusion, the results of the present study suggested that miR‑301a‑3p may serve as an oncogenic miRNA in TNBC by regulating MEOX2 expression.

View Figures

View References

1	Harbeck N, Penault-Llorca F, Cortes J, Gnant M, Houssami N, Poortmans P, Ruddy K, Tsang J and Cardoso F: Breast cancer. Nat Rev Dis Primers. 5(66)2019.PubMed/NCBI View Article : Google Scholar
2	Waks AG and Winer EP: Breast cancer treatment: A review. JAMA. 321:288–300. 2019.PubMed/NCBI View Article : Google Scholar
3	Huang J, Chan PS, Lok V, Chen X, Ding H, Jin Y, Yuan J, Lao XQ, Zheng ZJ and Wong MC: Global incidence and mortality of breast cancer: A trend analysis. Aging (Albany NY). 13:5748–5803. 2021.PubMed/NCBI View Article : Google Scholar
4	Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, et al: Molecular portraits of human breast tumours. Nature. 406:747–752. 2000.PubMed/NCBI View Article : Google Scholar
5	Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, et al: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 98:10869–10874. 2001.PubMed/NCBI View Article : Google Scholar
6	Gregory RI, Chendrimada TP, Cooch N and Shiekhattar R: Human RISC couples microRNA biogenesis and posttranscriptional gene silencing. Cell. 123:631–640. 2005.PubMed/NCBI View Article : Google Scholar
7	Mycko MP, Cichalewska M, Machlanska A, Cwiklinska H, Mariasiewicz M and Selmaj KW: MicroRNA-301a regulation of a T-helper 17 immune response controls autoimmune demyelination. Proc Natl Acad Sci USA. 109:E1248–E1257. 2012.PubMed/NCBI View Article : Google Scholar
8	Yu H, Li H, Qian H, Jiao X, Zhu X, Jiang X, Dai G and Huang J: Upregulation of miR-301a correlates with poor prognosis in triple-negative breast cancer. Med Oncol. 31(283)2014.PubMed/NCBI View Article : Google Scholar
9	Ma F, Zhang J, Zhong L, Wang L, Liu Y, Wang Y, Peng L and Guo B: Upregulated microRNA-301a in breast cancer promotes tumor metastasis by targeting PTEN and activating Wnt/β-catenin signaling. Gene. 535:191–197. 2014.PubMed/NCBI View Article : Google Scholar
10	Li X, Li J, Cai Y, Peng S, Wang J, Xiao Z, Wang Y, Tao Y, Li J, Leng Q, et al: Hyperglycaemia-induced miR-301a promotes cell proliferation by repressing p21 and Smad4 in prostate cancer. Cancer Lett. 418:211–220. 2018.PubMed/NCBI View Article : Google Scholar
11	Wang YG, Wang T, Shi M and Zhai B: Long noncoding RNA EPB41L4A-AS2 inhibits hepatocellular carcinoma development by sponging miR-301a-5p and targeting FOXL1. J Exp Clin Cancer Res. 38(153)2019.PubMed/NCBI View Article : Google Scholar
12	Li X, Zhong M, Wang J, Wang L, Lin Z, Cao Z, Huang Z, Zhang F, Li Y, Liu M and Ma X: miR-301a promotes lung tumorigenesis by suppressing Runx3. Mol Cancer. 18(99)2019.PubMed/NCBI View Article : Google Scholar
13	Hu H, Zhang Q, Chen W, Wu T, Liu S, Li X, Luo B, Zhang T, Yan G, Lu H and Lu Z: MicoRNA-301a promotes pancreatic cancer invasion and metastasis through the JAK/STAT3 signaling pathway by targeting SOCS5. Carcinogenesis. 41:502–514. 2020.PubMed/NCBI View Article : Google Scholar
14	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.PubMed/NCBI View Article : Google Scholar
15	von Minckwitz G, Huang CS, Mano MS, Loibl S, Mamounas EP, Untch M, Wolmark N, Rastogi P, Schneeweiss A, Redondo A, et al: Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med. 380:617–628. 2019.PubMed/NCBI View Article : Google Scholar
16	von Minckwitz G, Procter M, de Azambuja E, Zardavas D, Benyunes M, Viale G, Suter T, Arahmani A, Rouchet N, Clark E, et al: Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer. N Engl J Med. 377:122–131. 2017.PubMed/NCBI View Article : Google Scholar
17	Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M, Mackey J, Glaspy J, Chan A, Pawlicki M, et al: Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med. 365:1273–1283. 2011.PubMed/NCBI View Article : Google Scholar
18	Chen Z, Chen LY, Dai HY, Wang P, Gao S and Wang K: miR-301a promotes pancreatic cancer cell proliferation by directly inhibiting Bim expression. J Cell Biochem. 113:3229–3235. 2012.PubMed/NCBI View Article : Google Scholar
19	Xia X, Zhang K, Luo G, Cen G, Cao J, Huang K and Qiu Z: Downregulation of miR-301a-3p sensitizes pancreatic cancer cells to gemcitabine treatment via PTEN. Am J Transl Res. 9:1886–1895. 2017.PubMed/NCBI
20	Fang Y, Sun B, Xiang J and Chen Z: MiR-301a promotes colorectal cancer cell growth and invasion by directly targeting SOCS6. Cell Physiol Biochem. 35:227–236. 2015.PubMed/NCBI View Article : Google Scholar
21	Zhang W, Zhang T, Jin R, Zhao H, Hu J, Feng B, Zang L, Zheng M and Wang M: MicroRNA-301a promotes migration and invasion by targeting TGFBR2 in human colorectal cancer. J Exp Clin Cancer Res. 33(113)2014.PubMed/NCBI View Article : Google Scholar
22	Wang M, Li C, Yu B, Su L, Li J, Ju J, Yu Y, Gu Q, Zhu Z and Liu B: Overexpressed miR-301a promotes cell proliferation and invasion by targeting RUNX3 in gastric cancer. J Gastroenterol. 48:1023–1033. 2013.PubMed/NCBI View Article : Google Scholar
23	Xu XD, He XJ, Tao HQ, Zhang W, Wang YY, Ye ZY and Zhao ZS: Abnormal expression of miR-301a in gastric cancer associated with progression and poor prognosis. J Surg Oncol. 108:197–202. 2013.PubMed/NCBI View Article : Google Scholar
24	Zheng JZ, Huang YN, Yao L, Liu YR, Liu S, Hu X, Liu ZB and Shao ZM: Elevated miR-301a expression indicates a poor prognosis for breast cancer patients. Sci Rep. 8(2225)2018.PubMed/NCBI View Article : Google Scholar
25	Ohshima J, Haruta M, Arai Y, Kasai F, Fujiwara Y, Ariga T, Okita H, Fukuzawa M, Hata J, Horie H and Kaneko Y: Two candidate tumor suppressor genes, MEOX2 and SOSTDC1, identified in a 7p21 homozygous deletion region in a Wilms tumor. Genes Chromosomes Cancer. 48:1037–1050. 2009.PubMed/NCBI View Article : Google Scholar
26	Tian L, Tao Z, Ye H, Li G, Zhan Z and Tuo H: Over-expression of MEOX2 promotes apoptosis through inhibiting the PI3K/Akt pathway in laryngeal cancer cells. Neoplasma. 65:745–752. 2018.PubMed/NCBI View Article : Google Scholar
27	Ávila-Moreno F, Armas-López L, Álvarez-Moran A, López-Bujanda Z, Ortiz-Quintero B, Hidalgo-Miranda A, Urrea-Ramírez F, Rivera-Rosales RM, Vázquez-Manríquez E, Peña-Mirabal E, et al: Overexpression of MEOX2 and TWIST1 is associated with H3K27me3 levels and determines lung cancer chemoresistance and prognosis. PLoS One. 9(e114104)2014.PubMed/NCBI View Article : Google Scholar
28	Zhou P, Jiang W, Wu L, Chang R, Wu K and Wang Z: miR-301a is a candidate oncogene that targets the homeobox gene Gax in human hepatocellular carcinoma. Dig Dis Sci. 57:1171–1180. 2012.PubMed/NCBI View Article : Google Scholar